GlobeNewswire

electroCore to Participate at the 38th Annual Roth Conference
10/03/2026
ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference [...]
Aspargo Labs Gears Up to Bring Patented Liquid Erectile Dysfunction Treatment to UK Over-the-Counter Pharmacy Shelves
10/03/2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a pharmaceutical company commercializing an oral suspension spray technology, today announced it has submitted an [...]
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
10/03/2026
Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc [...]
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
10/03/2026
Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume [...]
New Report, “Let’s Talk Poop: Digestive Health, Denial, and the Cost of Staying Quiet,” Reveals Widespread Digestive Health Issues Accompanied By Stigma and Embarrassment
10/03/2026
National data from Oshi Health reveals that 50% of Americans have gut issues, but a majority simply think treatable symptoms are normal and don’t want to talk about them NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- A [...]
VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.
10/03/2026
Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide [...]
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
10/03/2026
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will establish an [...]
EVAA.AI Expands to Integrate with Multiple Eye Care EHR Systems
10/03/2026
Eye care practices can now access EVAA’s AI-powered billing automation and clinical documentation tools without changing their existing EHR system PORTLAND, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- EVAA.AI , part of the [...]
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
10/03/2026
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel [...]
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
10/03/2026
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation [...]
TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
10/03/2026
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free survival and overall [...]
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
10/03/2026
GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase [...]
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
10/03/2026
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy [...]
Press Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test
10/03/2026
PRESS RELEASE 10/03/2025, 08:00 CET Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test Idylla™ CDx MSI Test is the Second Fully Automated Companion Diagnostic Test Approval for Biocartis under [...]
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
10/03/2026
Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective [...]
OSE Immunotherapeutics confirme Marc Le Bozec comme Directeur Général pour mener la prochaine phase de croissance stratégique
10/03/2026
Nantes, France, 10 mars 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) annonce aujourd’hui la transition de Marc Le Bozec de Directeur Général par intérim à Directeur Général permanent, [...]
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
10/03/2026
Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March [...]
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
10/03/2026
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will [...]
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
10/03/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total Medical Device sales rose by [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum